Suppr超能文献

Ⅰ-Ⅲ期食管癌患者的预后评估。

Prognostic evaluation of esophageal cancer patients with stages I-III.

机构信息

Division of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China.

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

出版信息

Aging (Albany NY). 2020 Jul 23;12(14):14736-14753. doi: 10.18632/aging.103532.

Abstract

PURPOSE

The purpose of this study was to investigate the impact of clinicopathological factors and treatments on the overall survival (OS) and esophageal cancer-specific survival (ECSS) of stages I-III esophageal cancer (EC) patients and to establish a prognostic visual nomogram.

METHODS

We collected clinical data of patients diagnosed with stages I-III EC without receiving chemotherapy from 2004 to 2014 from the Surveillance, Epidemiology, and End Results (SEER) database. Prognoses were analyzed using the R language software, and nomograms were obtained according to the visual processing logistic regression model, which was verified using the Harrell C-index, receiver operating characteristic (ROC) curve, and calibration curve.

RESULTS

A total of 4,305 patients were selected, mostly white males. Most patients were over 60 years old and old age predicted poor prognosis. EC, primarily adenocarcinoma, occurred mostly in the lower third of the esophagus. About half of the patients had T1 (58.00%) and grade II (50.41%) cancer. Of all the patients, 2,448 was treated with surgery and the majority (n = 1,476; 64.85%) of these patients had stage I EC. Stages I-III patients underwent surgery had significantly better OS and ECSS, and endoscopic therapy was associated with the best outcome amongst all the surgical methods. 3.67% of the patients received radiotherapy, predominantly postoperative radiotherapy (2.69%). Older age, squamous cell carcinoma, overlapping lesion of the esophagus, and grades II and III were high-risk factors for poor OS and ECSS for stage I patients, whereas endoscopic therapy, esophagectomy, and esophagectomy with gastrectomy were low-risk factors. Stage II patients with older age, male sex, T3, N1, and grades II and III had shorter OS and ECSS, but patients with any surgical treatment had significantly longer OS and ECSS. T4, N1, and grade III correlated negatively with OS and ECSS in stage III patients, and any surgical treatment correlated positively with longer OS and ECSS. The OS and ECSS rates of stages I-III EC patients with a total score of more than 150 points in the nomogram were both only 40% after 3 years and 30% after 5 years. The C-index, ROC curve, and calibration curve indicated that the nomograms established in this study were suitable to assess patient prognosis.

CONCLUSION

The nomogram established in this study is an effective clinical tool to predict the prognosis of stages I-III EC patients without chemotherapy.

摘要

目的

本研究旨在探讨临床病理因素和治疗方法对 I-III 期食管癌(EC)患者总生存期(OS)和食管癌特异性生存期(ECSS)的影响,并建立预后可视化列线图。

方法

我们从 2004 年至 2014 年从监测、流行病学和最终结果(SEER)数据库中收集了未接受化疗的 I-III 期 EC 患者的临床数据。使用 R 语言软件对预后进行分析,并根据可视化处理逻辑回归模型获得列线图,通过 Harrell C 指数、接收者操作特征(ROC)曲线和校准曲线进行验证。

结果

共纳入 4305 例患者,主要为白人男性。大多数患者年龄超过 60 岁,年龄较大预示预后不良。EC 主要为腺癌,发生于食管下段。约一半的患者为 T1(58.00%)和 II 级(50.41%)癌症。所有患者中,2448 例接受了手术治疗,其中大多数(n=1476;64.85%)患者为 I 期 EC。I-III 期患者接受手术治疗的 OS 和 ECSS 明显更好,内镜治疗是所有手术方法中效果最好的。3.67%的患者接受了放疗,主要为术后放疗(2.69%)。对于 I 期患者,年龄较大、鳞状细胞癌、食管重叠病变以及 II 级和 III 级是 OS 和 ECSS 预后不良的高危因素,而内镜治疗、食管切除术和胃切除术是低危因素。对于 II 期患者,年龄较大、男性、T3、N1 和 II 级和 III 级与 OS 和 ECSS 较短相关,但任何手术治疗的患者 OS 和 ECSS 均明显较长。T4、N1 和 III 级与 III 期患者的 OS 和 ECSS 呈负相关,任何手术治疗均与 OS 和 ECSS 延长呈正相关。在列线图中总评分超过 150 分的 I-III 期 EC 患者,3 年后 OS 和 ECSS 率均仅为 40%,5 年后 OS 和 ECSS 率均仅为 30%。C 指数、ROC 曲线和校准曲线表明,本研究建立的列线图适合评估患者的预后。

结论

本研究建立的列线图是一种有效的临床工具,可预测未经化疗的 I-III 期 EC 患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f850/7425498/e7d90eb550e5/aging-12-103532-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验